SLC2A1 and renal cell carcinoma: Whatever the explanation, our result indicates that the inhibition of GLUT1 alone is highly unlikely to be a successful therapeutic strategy against RCC, while the ability to inhibit all glucose transporters might be the key to achieve clinical efficacy.